Teva Pharma (TEVA) Cut to Junk by S&P; to BB/Stable from BBB-/Watch
Tweet
Share
E-mail
Get Alerts TEVA Hot Sheet
Join SI Premium – FREE
Teva Pharma (NYSE: TEVA) Cut to Junk at S&P; to BB/Stable from BBB-/Watch
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
- Reliance Global Group names new CTO, COO, and EVP for AI push
- A.O. Smith executive chairman to retire, CEO to assume chairman role
Create E-mail Alert Related Categories
Corporate News, Credit RatingsRelated Entities
Standard & Poor'sSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
